Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by smush74on Aug 09, 2013 12:26pm

94 Views

Post# 21659615

RE:RE:RE:RE:New presentation.... Epuris 70% gross margins proof for doubters

thanks for the correction, but what I will be looking forward to in the next quarter will be how their market share is growing and just what they plan or have invisioned for the future and what they are intending to do with their money.

As for two three years down the road I won't try and predict a share price as they have yet to annouce anything substansive to warrant such a high valuation. 10$ for this year is very duable, but to have money just sitting in the bank won't cut it for most investors. A dividend, aquistion stock split if it does go to those levels are all questions that must be asked.

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports